Michigan Quality Improvement Consortium Clinical Practice Guideline Update Alert

Guideline:  Diagnosis and Management of Chronic Kidney Disease

Released:  October 2022

This alert provides a summary of only the recommendations which were updated. Refer to the complete guideline for all recommendations and level of evidence.

Updated recommendations include:

All adults at increased risk for CKD

•  Screening  Added: CKD-EPI Creatinine Equation (2021)
•  Testing for diagnosis and staging  Added: ‘unexpected’ eGFR <30

Adults with CKD

•  Core Principles of Treatment
  o  Added: Minimize iodinated contrast exposure (consider alternative measure if possible but not a complete avoidance necessary).
  o  Updated: Vaccines- edited for brevity and add COVID
  o  Added: SGLT2 inhibitors to “Cardiovascular risk modification…”
  o  Added: Consider assessment for and management of frailty as indicated.

•  Clinical Plan based on CKD Category
  o  Added eGFR levels and degrees of ACR:
    •  eGFR (G1-G5) and ACR (A1 <30 mg/g, A2 30-300 mg/g, A3 >300mg/g)
  o  Re-organization and edits for all Stages

Updated Reference
Chronic Kidney Disease Assessment and Management NICE guideline: